168 related articles for article (PubMed ID: 12444285)
1. Apoptotic and proliferative index after Alpha-1-adrenoceptor antagonist and/or finasteride treatment in benign prostatic hyperplasia.
Erdoğru T; Ciftcioglu MA; Emreoglu I; Usta MF; Koksal T; Ozbilim G; Gulkesen KH; Baykara M
Urol Int; 2002; 69(4):287-92. PubMed ID: 12444285
[TBL] [Abstract][Full Text] [Related]
2. Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor-beta expression in benign prostatic hyperplasia.
Glassman DT; Chon JK; Borkowski A; Jacobs SC; Kyprianou N
Prostate; 2001 Jan; 46(1):45-51. PubMed ID: 11170131
[TBL] [Abstract][Full Text] [Related]
3. Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia.
Chon JK; Borkowski A; Partin AW; Isaacs JT; Jacobs SC; Kyprianou N
J Urol; 1999 Jun; 161(6):2002-8. PubMed ID: 10332490
[TBL] [Abstract][Full Text] [Related]
4. Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis.
Kyprianou N; Benning CM
Cancer Res; 2000 Aug; 60(16):4550-5. PubMed ID: 10969806
[TBL] [Abstract][Full Text] [Related]
5. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.
Lepor H; Williford WO; Barry MJ; Haakenson C; Jones K
J Urol; 1998 Oct; 160(4):1358-67. PubMed ID: 9751354
[TBL] [Abstract][Full Text] [Related]
6. Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin.
Keledjian K; Borkowski A; Kim G; Isaacs JT; Jacobs SC; Kyprianou N
Prostate; 2001 Jul; 48(2):71-8. PubMed ID: 11433417
[TBL] [Abstract][Full Text] [Related]
7. Alpha1-adrenoceptor antagonists radiosensitize prostate cancer cells via apoptosis induction.
Cuellar DC; Rhee J; Kyprianou N
Anticancer Res; 2002; 22(3):1673-9. PubMed ID: 12168853
[TBL] [Abstract][Full Text] [Related]
8. Apoptotic impact of alpha1-blockers on prostate cancer growth: a myth or an inviting reality?
Tahmatzopoulos A; Kyprianou N
Prostate; 2004 Apr; 59(1):91-100. PubMed ID: 14991869
[TBL] [Abstract][Full Text] [Related]
9. Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia.
Kyprianou N; Litvak JP; Borkowski A; Alexander R; Jacobs SC
J Urol; 1998 Jun; 159(6):1810-5. PubMed ID: 9598465
[TBL] [Abstract][Full Text] [Related]
10. Effects of alpha(1)-adrenoceptor (alpha(1)-AR) antagonists on cell proliferation and apoptosis in the prostate: therapeutic implications in prostatic disease.
Kyprianou N; Chon J; Benning CM
Prostate Suppl; 2000; 9():42-6. PubMed ID: 11056502
[TBL] [Abstract][Full Text] [Related]
11. Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance.
Kyprianou N
J Urol; 2003 Apr; 169(4):1520-5. PubMed ID: 12629407
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of terazosin and finasteride in symptomatic benign prostatic hyperplasia: A comparative study.
Anwarul Islam AK; Kashem MA; Shameem IA; Kibria SA
Bangladesh Med Res Counc Bull; 2005 Aug; 31(2):54-61. PubMed ID: 16967810
[TBL] [Abstract][Full Text] [Related]
13. Combination of finasteride and doxazosin for the treatment of benign prostatic hyperplasia.
Doggrell SA
Expert Opin Pharmacother; 2004 May; 5(5):1209-11. PubMed ID: 15155119
[TBL] [Abstract][Full Text] [Related]
14. [Therapy of benign prostatic hyperplasia: terazosin or finasteride?].
Trinkler FB
Praxis (Bern 1994); 1997 Aug; 86(34):1305-6. PubMed ID: 9381019
[No Abstract] [Full Text] [Related]
15. Induction of apoptosis in the prostate by alpha1-adrenoceptor antagonists: a novel effect of "old" drugs.
Kyprianou N; Jacobs SC
Curr Urol Rep; 2000 Aug; 1(2):89-96. PubMed ID: 12084321
[TBL] [Abstract][Full Text] [Related]
16. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.
Lepor H; Williford WO; Barry MJ; Brawer MK; Dixon CM; Gormley G; Haakenson C; Machi M; Narayan P; Padley RJ
N Engl J Med; 1996 Aug; 335(8):533-9. PubMed ID: 8684407
[TBL] [Abstract][Full Text] [Related]
17. The effect of doxazosin, finasteride and combination therapy on nocturia in men with benign prostatic hyperplasia.
Johnson TM; Burrows PK; Kusek JW; Nyberg LM; Tenover JL; Lepor H; Roehrborn CG;
J Urol; 2007 Nov; 178(5):2045-50; discussion 2050-1. PubMed ID: 17869295
[TBL] [Abstract][Full Text] [Related]
18. Quinazoline-derived alpha1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an alpha1-adrenoceptor-independent action.
Benning CM; Kyprianou N
Cancer Res; 2002 Jan; 62(2):597-602. PubMed ID: 11809715
[TBL] [Abstract][Full Text] [Related]
19. Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting.
Keetch DW; Andriole GL; Ratliff TL; Catalona WJ
Urology; 1997 Dec; 50(6):901-5. PubMed ID: 9426721
[TBL] [Abstract][Full Text] [Related]
20. Long-term treatment with finasteride results in a clinically significant reduction in total prostate volume compared to placebo over the full range of baseline prostate sizes in men enrolled in the MTOPS trial.
Kaplan SA; Roehrborn CG; McConnell JD; Meehan AG; Surynawanshi S; Lee JY; Rotonda J; Kusek JW; Nyberg LM;
J Urol; 2008 Sep; 180(3):1030-2; discussion 1032-3. PubMed ID: 18639298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
